Penumbra, Inc. account plan
Medical device innovation company
At a glance
Penumbra makes thrombectomy, embolization and access devices to treat blood clots; $1,403.7 million revenue in FY2025, sale to Boston Scientific pending.
Penumbra, Inc. (Alameda, California; NYSE: PEN), founded in 2004, develops, manufactures and sells devices that remove blood clots from head to toe (pulmonary embolism, deep vein thrombosis, acute limb ischemia, ischemic stroke), plus embolization coils and neurovascular access catheters. Hospitals buy, guided by specialist physicians such as interventional radiologists, neuroradiologists and vascular surgeons; about 90% of revenue is direct sales and the United States is 77.8% of revenue. FY2025 revenue was $1,403.7 million, up 17.5%, with income from operations of $189.2 million and net income of $177.7 million. Penumbra had about 4,700 employees at December 31, 2025 and makes substantially all products in Alameda and Roseville, California. Boston Scientific agreed on January 14, 2026 to acquire it at $374 per share, with closing now expected in early 2027.
Business units
Thrombectomy
about 67.5% of FY2025 revenue ($947.9 million)Peripheral thrombectomy (Indigo System, Lightning Flash and Lightning Bolt with computer assisted vacuum thrombectomy, CAVT) for venous, pulmonary and arterial clot, and neuro thrombectomy (Penumbra System catheters, Penumbra ENGINE, THUNDERBOLT) for ischemic stroke. Revenue grew 16.2% in FY2025 and 18.1% in Q3 2026 to $279.2 million, on higher U.S. volume from new products.
Embolization and Access
about 32.5% of FY2025 revenue ($455.7 million)Peripheral embolization coils (Ruby, Ruby XL, POD, LANTERN), neuro embolization coils (SMART COIL, SwiftSET, SwiftMATCH), neurovascular access catheters and the Artemis Neuro Evacuation Device. Revenue grew 20.2% in FY2025 and 10.8% in Q3 2026 to $131.0 million; a dedicated peripheral embolization sales team of 50-plus reps was added in 2025.
Strategic priorities
- CAVT across the body
- Extend computer assisted vacuum thrombectomy through new Lightning Flash and Lightning Bolt generations in venous, pulmonary and arterial clot and bring it to stroke with THUNDERBOLT; Penumbra cites over 800,000 U.S. patients with VTE and arterial clot.
- Change pulmonary embolism protocols
- Use the STORM-PE trial, which showed CAVT superior to anticoagulation alone in intermediate-high-risk PE, to get hospitals, pulmonologists and hematologists to update PE protocols, one of the top priorities named for the next year.
- Embolization as an equal growth driver
- Grow embolization through the new 50-plus rep peripheral sales team, the Ruby XL launch and Swift coils in middle meningeal artery embolization.
- Gross margin expansion
- Management targeted a gross margin profile of over 70% by 2026; gross margin was 68.3% in Q3 2026.
- Close the Boston Scientific merger
- Complete the $374 per share sale, approved by stockholders, with closing expected in early 2027; Penumbra is to run as a standalone organization within Boston Scientific's cardiovascular group.
Latest results
In Q3 2026 (quarter ended September 30, 2026) revenue rose 15.6% to $410.1 million from $354.7 million, with Thrombectomy up 18.1% and Embolization and Access up 10.8%; international revenue rose 7.8% to $85.9 million. Gross margin improved to 68.3% from 67.8% on favorable product mix. SG&A rose 20.9% to $204.2 million, including $7.1 million of acquisition-related expenses, so income from operations was $50.7 million against $48.8 million. Over nine months revenue was $1,174.9 million (+15.4%) and income from operations flat at $130.0 million. Penumbra gives no numeric guidance while the merger is pending.
Investments and deals
- Costa Rica manufacturing plant
- A manufacturing facility and warehouse of approximately 330,000 square feet, now expected to cost approximately $91 million after an increase of approximately $31 million; $57.6 million had been paid by September 30, 2026.
- Sale to Boston Scientific
- Agreed January 14, 2026 at $374 per share, an enterprise value of approximately $14.5 billion, about 73% cash and 27% stock; termination fees are $525.0 million (Penumbra) and $900.0 million (Boston Scientific).
- Peripheral embolization sales team
- Over 50 dedicated peripheral embolization reps added in 2025 so the existing peripheral team could focus only on CAVT.
- Immersive healthcare exit
- The virtual reality business was wound down in 2024 at a cost of $115.3 million in impairment and other charges.
Challenges and risks
- Merger uncertainty
- The pending deal creates uncertainty for employees, customers and suppliers, adds transaction costs ($23.5 million of acquisition-related expenses over nine months of 2026) and has slipped from end-2026 to early 2027.
- Intense competition
- Boston Scientific, Medtronic, Stryker (now including Inari Medical) and Terumo compete, most with greater resources and the ability to bundle products.
- Rising SG&A holds back profit
- SG&A rose 23.5% over nine months of 2026 on headcount, deal costs and marketing events, keeping income from operations flat despite 15.4% revenue growth.
- Product concentration and regulatory timing
- Most revenue comes from a limited number of product families, and new products depend on FDA clearances; THUNDERBOLT spent a long period in 510(k) review.
- Hospital cost containment
- Hospitals are reimbursed at fixed MS-DRG rates regardless of device, and new products need value analysis committee approval, so cost-effectiveness drives adoption.
What leadership says
“We remain on track and are well-positioned to achieve a gross margin profile of over 70% by 2026”
“We are entering a very clear next phase of this company where the product innovation has progressed to the point where we really just have the most extraordinary best-in-class products across the whole portfolio.”
“So neuro is really set up for some significant growth”
“there was nothing one time about this quarter”
Where a supplier can help
- Costa Rica plant build-out
- The approximately $91 million Costa Rica facility, whose cost rose on evolving design requirements, needs construction, cleanroom, equipment and supply-chain partners.
- Clinical evidence and protocol adoption
- Turning STORM-PE into updated hospital PE protocols calls for medical education, real-world evidence and hospital outreach services aimed at pulmonologists and hematologists.
- Sales force productivity
- Penumbra's growth depends on adding salespeople and how fast they become effective, and SG&A is rising faster than revenue: sales training, CRM and field analytics vendors fit this need.
- Integration readiness
- The Boston Scientific deal, with synergies sought in G&A, operations and international go-to-market, opens work for integration, IT and finance consultants before and after closing.
- Manufacturing margin
- The target of a gross margin over 70% points to suppliers of automation, quality and component cost reduction for the Alameda and Roseville plants.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Penumbra, Inc.?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025
- Penumbra, Inc. (Alameda, California; NYSE: PEN) calls itself "the world's leading thrombectomy company": it develops, manufactures and sells devices that remove blood clots "from head-to-toe" (ischemic stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia), plus embolization coils and neurovascular access catheters. It reports one operating segment.
- FY2025 revenue was $1,403.7 million, up 17.5% from $1,194.6 million; income from operations rose to $189.2 million (13.5% of revenue) from $9.3 million in 2024, when the exit of the immersive healthcare business cost $115.3 million in impairment and other charges. Net income was $177.7 million.
- Thrombectomy revenue was $947.9 million (+16.2%; U.S. thrombectomy +19.3%); Embolization and Access revenue was $455.7 million (+20.2%; U.S. +25.4%). Prices were substantially unchanged: growth came from volume and new products.
- The United States is 77.8% of revenue ($1,091.8 million, +21.0%); international sales were $311.9 million (+6.6%). About 90% of revenue is direct sales; distributors were 10.0% of revenue in 2025.
- Gross margin rose 3.9 points to 67.1%; R&D was $89.8 million (6.4% of revenue) and SG&A $663.4 million (47.3%). Operating cash flow was $238.7 million; year-end cash was $186.9 million plus $357.9 million of marketable investments.
- 2025 launches: Lightning Flash 3.0, Lightning Bolt 12, Lightning Bolt 6X with TraX (computer assisted vacuum thrombectomy, CAVT), Ruby XL coils and SwiftSET neuro coils; THUNDER, an IDE study of CAVT in stroke, completed enrollment in September 2024.
- Manufacturing is in-house in Alameda and Roseville, California; in 2025 Penumbra agreed to buy property and build a manufacturing plant and warehouse in Costa Rica (capex of $63.7 million in 2025, mainly for it).
- On January 14, 2026 Penumbra agreed to be acquired by Boston Scientific at $374 per share (enterprise value about $14.5 billion; 73% cash / 27% stock), expected to close by the end of 2026; termination fees are $525.0 million (Penumbra) and $900.0 million (Boston Scientific).
- About 4,700 employees at December 31, 2025. Main competitors named: Boston Scientific, Medtronic, Stryker (now including Inari Medical) and Terumo. Key risks: merger uncertainty, competition, reliance on a limited number of product families, supplier dependence, reimbursement and FDA clearances.
- Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (quarter ended September 30, 2026) revenue was $410.1 million, up 15.6% from $354.7 million; nine-month revenue was $1,174.9 million, up 15.4%.
- Thrombectomy revenue grew 18.1% to $279.2 million in the quarter on higher U.S. volume from new products and deeper penetration; Embolization and Access grew 10.8% to $131.0 million. Prices were substantially unchanged.
- International revenue rose 7.8% to $85.9 million, 20.9% of revenue (22.5% a year earlier).
- Gross margin was 68.3% in Q3 (67.8% a year earlier) and 68.0% over nine months (66.8%), driven by favorable product mix.
- SG&A rose 20.9% to $204.2 million, including $7.1 million of acquisition-related expenses for the pending Boston Scientific acquisition (nine months: $23.5 million); income from operations was $50.7 million in Q3 and $130.0 million over nine months, flat year on year.
- The Boston Scientific merger ($374 per share, enterprise value about $14.5 billion) has been approved by Penumbra's stockholders; closing is now expected in early 2027, subject to regulatory approvals.
- Cash and cash equivalents of $254.3 million plus $419.3 million of marketable investments at September 30, 2026; nine-month operating cash flow $174.6 million.
- The Costa Rica plant and warehouse (about 330,000 square feet) is now expected to cost approximately $91 million, after an increase of about $31 million; $57.6 million had been paid by September 30, 2026.
- THUNDERBOLT now appears among the neuro thrombectomy products and SwiftMATCH among the neuro embolization coils.
- Boston Scientific / Penumbra acquisition conference call transcript (Rule 425 filing)
- Conference call of January 15, 2026 announcing Boston Scientific's agreement to acquire Penumbra, with Penumbra founder, Chairman and CEO Adam Elsesser alongside Boston Scientific CEO Michael F. Mahoney and CFO Jonathan Monson.
- Price: $374 per Penumbra share in cash and stock, total consideration of $15 billion (about $11 billion cash, $4 billion Boston Scientific stock; 73% / 27%).
- Elsesser pre-announced fourth-quarter revenue growth of 21.4% to 22% and full-year preliminary revenue of $1.4 billion, growth of about 17.3% to 17.5%.
- Elsesser said he will take Boston Scientific stock for all his Penumbra shares and join the Boston Scientific board at close.
- Boston Scientific plans to run Penumbra "essentially as a standalone organization within the cardiovascular group"; Mahoney thanked "more than 4,500 Penumbra employees".
- Synergies: over $200 million of operating income impact by year three, from revenue acceleration outside the U.S. and efficiencies in G&A and operations.
- Mahoney sees commercial synergies at the vascular surgeon, interventional radiology and interventional cardiology call points, and help scaling Penumbra's Costa Rica manufacturing.
- Elsesser on neuro: confident in ischemic stroke with new products coming; embolization of the middle meningeal artery is early but "could be a significant growth opportunity over the next two, three years".
- Penumbra Q3 2025 earnings call transcript
- Penumbra's Q3 2025 earnings call (November 5, 2025), with CEO Adam Elsesser, CFO Maggie Yuen and Chief Medical Officer Shruthi Narayan: its last regular call before the Boston Scientific deal.
- Q3 2025 revenue was $354.7 million (+17.8% reported, +16.9% constant currency); U.S. revenue $275 million (+21.5%); U.S. thrombectomy $192 million (+18.5%) with the VTE franchise up 34%; U.S. embolization and access $83 million (+29.2%); international $79.7 million (+6.6%).
- Gross margin 67.8% (+130 basis points); non-GAAP operating income $48.8 million (13.8% of revenue); cash and marketable securities $470.3 million and no debt.
- 2025 revenue guidance raised to $1.375-$1.380 billion; U.S. thrombectomy growth of 20%-21% reiterated; target of a gross margin over 70% by 2026.
- STORM-PE, a randomized trial of CAVT plus anticoagulation against anticoagulation alone in intermediate-high-risk PE, showed CAVT superior; management sees it as "a major catalyst" and will push hospitals to update protocols as a top priority.
- A new dedicated peripheral embolization sales team of 50-plus reps drove 21.2% sequential growth in embolization revenue after the Ruby XL launch.
- Thunderbolt (CAVT for stroke) was still in FDA 510(k) review; stroke market volumes declined slightly in Q3, though Penumbra kept gaining share.
- China headwinds were expected to be minimal by early 2026; international markets outside China grew double digits.
Questions about Penumbra, Inc.
What does Penumbra do?
Penumbra develops, manufactures and sells medical devices that remove blood clots from head to toe, including CAVT thrombectomy systems, plus embolization coils and neurovascular access catheters.
What is Penumbra's revenue?
FY2025 revenue was $1,403.7 million, up 17.5%. Q3 2026 revenue was $410.1 million, up 15.6%.
How many employees does Penumbra have?
Penumbra had about 4,700 employees at December 31, 2025.
Who is acquiring Penumbra?
Boston Scientific agreed on January 14, 2026 to acquire Penumbra at $374 per share, an enterprise value of approximately $14.5 billion; stockholders approved it and closing is expected in early 2027.
Who leads Penumbra?
Founder Adam Elsesser is Chairman and CEO; Maggie Yuen is Chief Financial Officer.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)